medicina59巻13号

2022年12月発行

特集 令和の頭痛診療—プライマリ・ケア医のためのガイド 頭痛診療One-up

新規CGRP関連抗体薬の特徴，使い方

著者： 山王直子¹²

所属機関： ¹品川ストリングスクリニック ²日本医科大学脳神経外科学

ページ範囲：P.2388 - P.2395

Point
◎片頭痛の発症に深く関与するカルシトニン遺伝子関連ペプチド（CGRP）を標的とした片頭痛発症抑制薬が2021年本邦においても認可され，実臨床での治療が開始された．
◎抗CGRPモノクロナール抗体ガルカネズマブ，フレマネズマブ，抗CGRP受容体抗体エレヌマブの3製剤いずれも従来の内服の片頭痛予防薬と比較して片頭痛の病態に即した治療薬であり，有効性が高いと考えられる．
◎新規CGRP関連抗体薬の特徴，使い方について欧州ガイドライン2022-updateを参考に1年間の治療経験を踏まえて解説する．

参考文献

1）Sakai F, Igarashi H：Prevalence of migraine in Japan；A nationwide survey. Cephalalgia 17：15-22, 1997

2）Messali A, et al：Direct and indirect costs of chronic and episodic migraine in the United States；A web-based survey. Headache 56：306-322, 2016

3）Moskowitz MA：The neurobiology of vascular head pain. Ann Neurol 16：157-168, 1984

4）CGRP関連薬剤（CGRP受容体拮抗薬，抗CGRP抗体，抗CGRP受容体抗体）は片頭痛の予防に有効か．日本神経学会，他（監），「頭痛の診療ガイドライン」作成委員会（編）：頭痛の診療ガイドライン2021，医学書院，pp 239-247, 2021

5）Amara SG, et al：Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 298：240-244, 1982

6）Rosenfeld MG, et al：Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature 304：129-135, 1983

7）Goadsby PJ, et al：Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28：183-187, 1990

8）Tvedskov JF, et al：No increase of calcitonin gene-related peptide in jugular blood during migraine. Ann Neurol 58：561-568, 2005

9）Cernuda-Morollón E, et al：Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology 81：1191-1196, 2013

10）Lassen LH, et al：CGRP may play a causative role in migraine. Cephalalgia 22：54-61, 2002

11）Hansen JM, et al：Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia 30：1179-1186, 2010

12）Brain SD, et al：Calcitonin gene- related peptide is a potent vasodilator. Nature 313：54-56, 1985

13）Peres MFP, et al：Patients' preference for migraine preventive therapy. Headache 47：540-545, 2007

14）Serrano D, et al：Fluctuations in episodic and chronic migraine status over the course of 1 year；Implications for diagnosis, treatment and clinical trial design. J Headache Pain 18：101, 2017

15）Hay DL, Walker CS：CGRP and its receptors. Headache 57：625-636, 2017

16）Walker CS, Hay DL：CGRP in the trigeminovascular system；A role for CGRP, adrenomedullin and amylin receptors?. Br J Pharmacol 170：1293-1307, 2013

17）Hay DL, et al：Update on the pharmacology of calcitonin/CGRP family of peptides；IUPHAR Review 25. Br J Pharmacol 175：3-17, 2018

18）Foltz IN, et al：Evolution and emergence of therapeutic monoclonal antibodies；What cardiologists need to know. Circulation 127：2222-2230, 2013

19）Stauffer VL, et al：Evaluation of galcanezumab for the prevention of episodic migraine；The EVOLVE-1 randomized clinical trial. JAMA Neurol 75：1080-1088, 2018

20）Skljarevski V, et al：Efficacy and safety of galcanezumab for the prevention of episodic migraine；Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia 38：1442-1454, 2018

21）Forderreuther S, et al：Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent；Data from the phase 3, randomized, double-blind, placebo- controlled EVOLVE-1, EVOLVE-2, and REGAIN studies. J Headache Pain 19：121, 2018

22）Dodick DW, et al：Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine. Cephalalgia 41：340-352, 2021

23）Manoukian R, et al：Effects of monoclonal antagonist antibodies on calcitonin gene-related peptide receptor function and trafficking. J Headache Pain 20：44, 2019

24）Sakai F, et al：A randomized phase 2 study of erenumab for the prevention of episodic migraine in Japanese adults. Headache 59：1731-1742, 2019

25）Ornello R, et al：Conversion from chronic to episodic migraine in patients treated with erenumab；Real-life data from an Italian region. J Headache Pain 21：102, 2020

26）Ashina M, et al：Long-term efficacy and safety of erenumab in migraine prevention；Results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol 28：1716-1725, 2021

27）Dodick DW, et al：Effect of fremanezumab compared with placebo for prevention of episodic migraine；A randomized clinical trial. JAMA 319：1999-2008, 2018

28）Silberstein SD, et al：The impact of fremanezumab on medication overuse in patients with chronic migraine；Subgroup analysis of the HALO CM study. J Headache Pain 21：114, 2020

29）Sacco S, et al：European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 20：6, 2019

30）Sacco S, et al：European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention-2022 update. J Headache Pain 23：67, 2022

31）Hines DM, et al：Erenumab patient characteristics, medication adherence, and treatment patterns in the United States. Headache 61：590-602, 2021

32）Overeem LH, et al：Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine；A multi-center retrospective cohort study. Cephalalgia 42：291-301, 2022